Literature DB >> 8452962

Induction and assessment of immunity at enteromucosal surfaces in humans: implications for vaccine development.

C Czerkinsky1, A M Svennerholm, J Holmgren.   

Abstract

It is now almost axiomatic that vaccines against enteric infections must be able to stimulate the gut lymphoid tissue to be efficacious and that this goal is usually better achieved by administering immunogens orally rather than parenterally. On the basis of the notion of a common mucosal immunologic system that provides immune reactivity not only at the site of antigen deposition but also at remote mucosal sites, there is much interest in developing oral vaccines against infections in the respiratory and urogenital tracts. Recent studies indicate that oral administration of small amounts of protein antigens that are chemically or genetically linked to intestinal binding carrier molecules (such as the B subunit of cholera toxin) can evoke vigorous mucosal and extramucosal immune responses. The apparent compartmentalization of systemic and mucosal immune responses may explain not only why parenteral vaccines are just partly effective in protecting against mucosal pathogens but also why currently employed immunoanalytical methods do not provide accurate information regarding mucosal immune status. Following the developments of oral vaccines against infections due to Vibrio cholerae and enterotoxigenic Escherichia coli, two archetypes of enteropathogens, we have devoted extensive efforts to gaining insight into the humoral and cellular events involved in the development of protective immunity in the human intestinal tract. We have developed preparative and analytical methods for studying vaccine-induced intestinal and extraintestinal immune responses in humans. These include techniques for collecting intestinal fluid and lymphoid cells as well as procedures to quantitate secretory antibodies and lymphokines secreted by activated intestinal immunocytes. These developments should serve the dual purpose of facilitating analyses of human mucosal immune responses in general and assessing the immunogenicity of enteric vaccines in particular.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8452962     DOI: 10.1093/clinids/16.supplement_2.s106

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  17 in total

1.  Kinetics of local and systemic immune responses to an oral cholera vaccine given alone or together with acetylcysteine.

Authors:  J Kilhamn; M Jertborn; A M Svennerholm
Journal:  Clin Diagn Lab Immunol       Date:  1998-03

Review 2.  Progress towards development of a vaccine for amebiasis.

Authors:  S L Stanley
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

3.  Dose-dependent circulating immunoglobulin A antibody-secreting cell and serum antibody responses in Swedish volunteers to an oral inactivated enterotoxigenic Escherichia coli vaccine.

Authors:  M Jertborn; C Ahrén; A M Svennerholm
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

4.  Lipopolysaccharide- and cholera toxin-specific subclass distribution of B-cell responses in cholera.

Authors:  F Qadri; F Ahmed; M M Karim; C Wenneras; Y A Begum; M Abdus Salam; M J Albert; J R McGhee
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

5.  Immunoglobulin A-deficient mice exhibit altered T helper 1-type immune responses but retain mucosal immunity to influenza virus.

Authors:  Yongxin Zhang; Susan Pacheco; Catherine L Acuna; Kirsten C Switzer; Ying Wang; Xyanthine Gilmore; Gregory R Harriman; Innocent N Mbawuike
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

Review 6.  Assessing mucosal humoral immunity.

Authors:  S J Challacombe
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

Review 7.  Vaccination strategies for mucosal immune responses.

Authors:  P L Ogra; H Faden; R C Welliver
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

8.  Mucosal immunogenicity of a holotoxin-like molecule containing the serine-rich Entamoeba histolytica protein (SREHP) fused to the A2 domain of cholera toxin.

Authors:  F Sultan; L L Jin; M G Jobling; R K Holmes; S L Stanley
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

Review 9.  Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues.

Authors:  Samuel K Lai; Ying-Ying Wang; Justin Hanes
Journal:  Adv Drug Deliv Rev       Date:  2008-12-13       Impact factor: 15.470

10.  Development of immunoglobulin M memory to both a T-cell-independent and a T-cell-dependent antigen following infection with Vibrio cholerae O1 in Bangladesh.

Authors:  Emily A Kendall; Abdullah A Tarique; Azim Hossain; Mohammad Murshid Alam; Mohammad Arifuzzaman; Nayeema Akhtar; Fahima Chowdhury; Ashraful I Khan; Regina C Larocque; Jason B Harris; Edward T Ryan; Firdausi Qadri; Stephen B Calderwood
Journal:  Infect Immun       Date:  2009-10-26       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.